May 15th 2024
Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma.
February 27th 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lenalidomide Approved by the FDA for the Treatment of Mantle Cell Lymphoma
June 6th 2013Lenalidomide has been approved to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.
Read More
Study of Inotuzumab Ozogamicin Halted After Interim Analysis
May 22nd 2013A phase III study of inotuzumab ozogamicin for patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy was halted after a scheduled interim analysis.
Read More